Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathway
Summary: Diabetic cataract (DC), a well-recognized complication in diabetic patients, can progress to blindness if not adequately managed, with currently limited therapeutic strategies. Icariin (ICA), a natural compound derived from Epimedium, has been demonstrated exhibiting anti-inflammatory and a...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225010570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849434851878371328 |
|---|---|
| author | Yakun Wang Wenxian Yang Hangjia Zuo Shuhao Zeng Xianyang Liu Fan Cao Hui Yang Shangze Gao Meng Tian Xiang Gao Yongguo Xiang Fanfan Huang Baorui Chu Chao Wu Hui Feng Wenjuan Wan Shijie Zheng Shengping Hou Ke Hu |
| author_facet | Yakun Wang Wenxian Yang Hangjia Zuo Shuhao Zeng Xianyang Liu Fan Cao Hui Yang Shangze Gao Meng Tian Xiang Gao Yongguo Xiang Fanfan Huang Baorui Chu Chao Wu Hui Feng Wenjuan Wan Shijie Zheng Shengping Hou Ke Hu |
| author_sort | Yakun Wang |
| collection | DOAJ |
| description | Summary: Diabetic cataract (DC), a well-recognized complication in diabetic patients, can progress to blindness if not adequately managed, with currently limited therapeutic strategies. Icariin (ICA), a natural compound derived from Epimedium, has been demonstrated exhibiting anti-inflammatory and anti-oxidant, but its impact on diabetic cataracts remains elusive. In this study, we used both in vitro SRA01/04 cells and in vivo SD rats’ model to explored the protective effects of ICA in cataract formation. Following network pharmacology, proteomic and surface plasmon resonance (SPR) analyses further demonstrated that ICA interacts with insulin-like growth factor-binding protein-3 (IGFBP3) and modulates oxidative stress as well as apoptosis via the PI3K/AKT signaling pathway. These findings collectively demonstrated that ICA could alleviate high glucose-induced oxidative stress and cell apoptosis in vitro and in vivo, suggesting that ICA is a potent natural compound with protective effects in DC, offering an effective therapeutic approach for the disease management. |
| format | Article |
| id | doaj-art-b262322cd99b4510b8e232b84dae1ad4 |
| institution | Kabale University |
| issn | 2589-0042 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj-art-b262322cd99b4510b8e232b84dae1ad42025-08-20T03:26:30ZengElsevieriScience2589-00422025-07-0128711279610.1016/j.isci.2025.112796Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathwayYakun Wang0Wenxian Yang1Hangjia Zuo2Shuhao Zeng3Xianyang Liu4Fan Cao5Hui Yang6Shangze Gao7Meng Tian8Xiang Gao9Yongguo Xiang10Fanfan Huang11Baorui Chu12Chao Wu13Hui Feng14Wenjuan Wan15Shijie Zheng16Shengping Hou17Ke Hu18The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, China; Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, China; Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, China; Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, ChinaThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, China; Corresponding authorBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China; Corresponding authorThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing 400016, China; Corresponding authorSummary: Diabetic cataract (DC), a well-recognized complication in diabetic patients, can progress to blindness if not adequately managed, with currently limited therapeutic strategies. Icariin (ICA), a natural compound derived from Epimedium, has been demonstrated exhibiting anti-inflammatory and anti-oxidant, but its impact on diabetic cataracts remains elusive. In this study, we used both in vitro SRA01/04 cells and in vivo SD rats’ model to explored the protective effects of ICA in cataract formation. Following network pharmacology, proteomic and surface plasmon resonance (SPR) analyses further demonstrated that ICA interacts with insulin-like growth factor-binding protein-3 (IGFBP3) and modulates oxidative stress as well as apoptosis via the PI3K/AKT signaling pathway. These findings collectively demonstrated that ICA could alleviate high glucose-induced oxidative stress and cell apoptosis in vitro and in vivo, suggesting that ICA is a potent natural compound with protective effects in DC, offering an effective therapeutic approach for the disease management.http://www.sciencedirect.com/science/article/pii/S2589004225010570MedicineMolecular biologyMolecular medicine |
| spellingShingle | Yakun Wang Wenxian Yang Hangjia Zuo Shuhao Zeng Xianyang Liu Fan Cao Hui Yang Shangze Gao Meng Tian Xiang Gao Yongguo Xiang Fanfan Huang Baorui Chu Chao Wu Hui Feng Wenjuan Wan Shijie Zheng Shengping Hou Ke Hu Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathway iScience Medicine Molecular biology Molecular medicine |
| title | Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathway |
| title_full | Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathway |
| title_fullStr | Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathway |
| title_full_unstemmed | Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathway |
| title_short | Icariin interacts with IGFBP3 to alleviate diabetic cataract through PI3K/AKT signaling pathway |
| title_sort | icariin interacts with igfbp3 to alleviate diabetic cataract through pi3k akt signaling pathway |
| topic | Medicine Molecular biology Molecular medicine |
| url | http://www.sciencedirect.com/science/article/pii/S2589004225010570 |
| work_keys_str_mv | AT yakunwang icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT wenxianyang icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT hangjiazuo icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT shuhaozeng icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT xianyangliu icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT fancao icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT huiyang icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT shangzegao icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT mengtian icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT xianggao icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT yongguoxiang icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT fanfanhuang icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT baoruichu icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT chaowu icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT huifeng icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT wenjuanwan icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT shijiezheng icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT shengpinghou icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway AT kehu icariininteractswithigfbp3toalleviatediabeticcataractthroughpi3kaktsignalingpathway |